NCT06667908

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 130 (estimated)
• Sponsor: Johnson & Johnson Enterprise Innovation Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

Type	Name	Description
DRUG	JNJ-90301900	JNJ-90301900 will be injected intratumorally and/or intranodally.
BIOLOGICAL	Durvalumab	Durvalumab will be administered as intravenous (IV) infusion as cIT.
RADIATION	Concurrent Chemo/Radiation Therapy (cCRT)	Radiation by intensity modulated radiation therapy (IMRT) will be administered.
DRUG	Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin	Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.
DRUG	Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel	Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Timeline

• Start date: 2024-12-06
• Primary completion: 2028-12-31
• Completion: 2028-12-31
• First posted: 2024-10-31
• Last updated: 2026-04-14

Locations

40 sites across 10 countries: United States, Australia, Brazil, China, France, Hong Kong, Netherlands, Spain, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study